NewsBenzingaSystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 SystImmune And Bristol Myers Report Phase 3 PANKU-Breast01 Interim Analysis Shows Izalontamab Brengitecan Cuts Progression Or Death Risk By 59% Vs Chemotherapy in HR+/HER2- Metastatic Breast Cancer; Results To Be Presented At ESMO 2026 Benzinga 2026.10.23 11:36 (GMT+0) Open on Benzinga Other news LDP: The Family Favorite But Not Enough (NYSE:LDP) Betterware: Tupperware Looks Better, But Jafra Looks Worse (NYSE:BWMX) Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws Tower Semiconductor: The Silicon Photonics Opportunity Is Taking Shape (NASDAQ:TSEM) Enovis Screens Cheap, But There Is A Continued M&A Overhang (NYSE:ENOV) Coeur Mining: The Cost Trick Every Silver Investor Should Understand (NYSE:CDE)
Palo Alto CEO Nikesh Arora Warns Companies to Assume They Will Get ‘Breached’ and Fix Their ‘Technology Debt’ as AI Uncovers Critical Software Flaws
